Stockscreener 앱 받기
11.53
3.88%
-0.465
시간 외 거래:
11.56
0.035
+0.30%
전일 마감가:
$11.99
열려 있는:
$11.42
하루 거래량:
468.91K
Relative Volume:
0.79
시가총액:
$582.18M
수익:
$89.04M
순이익/손실:
$-241.08M
주가수익비율:
-2.1911
EPS:
-5.26
순현금흐름:
$-194.72M
1주 성능:
-12.42%
1개월 성능:
+10.50%
6개월 성능:
+10.82%
1년 성능:
+31.56%
1일 변동 폭
$11.38
$11.96
1주일 범위
$11.38
$13.40
52주 변동 폭
$5.035
$13.93
Regenxbio Inc Stock (RGNX) Company Profile
명칭
Regenxbio Inc
전화
240-552-8181
주소
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
RGNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
11.53 | 605.67M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-11 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-02-07 | 재개 | Raymond James | Outperform |
| 2024-11-15 | 재개 | Morgan Stanley | Overweight |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-06-07 | 개시 | Goldman | Buy |
| 2024-03-11 | 개시 | H.C. Wainwright | Buy |
| 2024-03-08 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 재개 | Raymond James | Outperform |
| 2023-11-01 | 개시 | Stifel | Buy |
| 2023-06-02 | 개시 | Robert W. Baird | Outperform |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Wedbush | Neutral |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-01-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-06-25 | 재개 | BofA/Merrill | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-14 | 재개 | Raymond James | Outperform |
| 2019-06-05 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-25 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-02-05 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 재확인 | Chardan Capital Markets | Buy |
| 2018-11-08 | 재확인 | BofA/Merrill | Neutral |
| 2018-08-08 | 재확인 | Chardan Capital Markets | Buy |
| 2018-07-23 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 재확인 | Chardan Capital Markets | Buy |
| 2018-05-09 | 재확인 | Barclays | Overweight |
| 2018-04-09 | 재확인 | Chardan Capital Markets | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 개시 | Mizuho | Neutral |
| 2017-11-09 | 재개 | Morgan Stanley | Overweight |
모두보기
Regenxbio Inc 주식(RGNX)의 최신 뉴스
REGENXBIO (NASDAQ:RGNX) Stock Price Down 9.8%Here's What Happened - MarketBeat
Regenxbio Inc expected to post a loss of $1.31 a shareEarnings Preview - TradingView
Will REGENXBIO Inc. (RB0) stock announce special dividend2025 Market Overview & Consistent Income Trade Ideas - newser.com
Will REGENXBIO Inc. stock split again soonJuly 2025 Volume & Fast Moving Market Watchlists - newser.com
How REGENXBIO Inc. stock responds to policy changesTrade Performance Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Using economic indicators to assess REGENXBIO Inc. potentialQuarterly Trade Review & Weekly Market Pulse Updates - newser.com
Is now a turning point for REGENXBIO Inc.Gap Down & Expert Approved Trade Ideas - newser.com
Will REGENXBIO Inc. (RB0) stock sustain uptrend momentumJuly 2025 Gainers & Weekly Breakout Opportunity Watchlist - newser.com
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulusWeekly Gains Report & Community Verified Trade Alerts - newser.com
Will REGENXBIO Inc. stock go up soon2025 Breakouts & Breakdowns & Weekly Breakout Opportunity Watchlist - newser.com
Reversal indicators forming on REGENXBIO Inc. stock2025 Risk Factors & Reliable Momentum Entry Alerts - newser.com
REGENXBIO Inc. stock daily chart insightsJuly 2025 Drop Watch & Capital Efficient Trade Techniques - newser.com
What data driven models say about REGENXBIO Inc.’s future2025 Market Sentiment & AI Optimized Trade Strategies - newser.com
Visualizing REGENXBIO Inc. stock with heatmapsJuly 2025 Highlights & Risk Managed Investment Strategies - newser.com
Will REGENXBIO Inc. stock see PE expansionQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Historical volatility pattern of REGENXBIO Inc. visualizedEarnings Overview Summary & Long-Term Safe Investment Plans - newser.com
Should I buy REGENXBIO Inc. (RB0) stock before earnings seasonTrade Analysis Report & Expert Curated Trade Setup Alerts - newser.com
Is REGENXBIO Inc. stock undervalued vs historical averagesGold Moves & Detailed Earnings Play Alerts - newser.com
Using Ichimoku Cloud for REGENXBIO Inc. technicals2025 Price Targets & AI Driven Stock Movement Reports - newser.com
Price momentum metrics for REGENXBIO Inc. explainedMarket Sentiment Report & Entry Point Confirmation Alerts - newser.com
Analyzing recovery setups for REGENXBIO Inc. investorsMarket Performance Recap & Safe Entry Momentum Tips - newser.com
Can REGENXBIO Inc. (RB0) stock deliver strong annual returnsWeekly Trade Summary & Growth-Oriented Investment Plans - newser.com
Why REGENXBIO Inc. stock is considered a top pickAnalyst Upgrade & Daily Oversold Stock Bounce Ideas - newser.com
Why REGENXBIO Inc. stock appeals to dividend seekersPortfolio Value Summary & Long-Term Growth Plans - newser.com
Is REGENXBIO Inc. stock overvalued by current metricsCEO Change & Weekly Watchlist for Hot Stocks - newser.com
AlphaQuest LLC Cuts Position in REGENXBIO Inc. $RGNX - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
RegenXBio (RGNX) Receives a Buy from H.C. Wainwright - The Globe and Mail
Will REGENXBIO Inc. (RB0) stock outperform Dow Jones2025 EndofYear Setup & Precise Swing Trade Alerts - newser.com
REGENXBIO concludes subject enrolment in trial of RGX-202 - Clinical Trials Arena
Regenxbio Inc (RGNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):